NCT04451434 is a Phase 1 clinical trial of Danicopan in Healthy, sponsored by Alexion Pharmaceuticals, Inc..

Who is sponsoring NCT04451434?

NCT04451434 is sponsored by Alexion Pharmaceuticals, Inc..

What drugs are being tested in NCT04451434?

Interventions in NCT04451434: Danicopan.

Is NCT04451434 still recruiting?

NCT04451434 is currently completed. Last updated 15 February 2021.

Last reviewed 2021-02-15 · How we verify

NCT04451434

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Danicopan in Participants of Japanese Descent

Completed Phase 1 Last updated 15 February 2021

What this trial tests

Phase 1 trial testing Danicopan in Healthy in 9 participants. Completed in 28 September 2020.

Timeline

17 August 2020

Primary endpoint
28 September 2020

28 September 2020

Quick facts

Lead sponsor	Alexion Pharmaceuticals, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	17 August 2020
Primary completion	28 September 2020
Estimated completion	28 September 2020
Sites	1 location across Australia

Drugs / interventions tested

Danicopan — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Alexion Pharmaceuticals, Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of danicopan after a single-dose oral administration under fed and fasting conditions to participants of Japanese descent.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway.
Barratt J, Weitz I. · · 2021 · cited 88× · PMID 34566967 · DOI 10.3389/fimmu.2021.712572

Verify or expand the search:

Other trials of Danicopan

Trials testing the same drug.

NCT07413250 — Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis o · active not recruiting
NCT07413679 — Long-term Safety of Danicopan: IPIG Registry-based Cohort Study · active not recruiting
NCT06449001 — Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinical · Phase 3 · recruiting
NCT05389449 — A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Par · Phase 3 · active not recruiting
NCT05019521 — A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration · Phase 2 · terminated

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Alexion Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT06015750 — Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia · Phase 4 · withdrawn
NCT07352423 — Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants · Phase 1 · recruiting
NCT07221838 — A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab · Phase 4 · recruiting
NCT07413250 — Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis o · active not recruiting
NCT07308574 — Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04451434 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alexion Pharmaceuticals, Inc.
Last refreshed: 15 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04451434.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing